GlassScriptPhysician profile
James A Kuzman
NPI 1275760860
$2,240.59
in general payments reported to CMS, 2019-2025
14 companies · $72.14 in 2025
The $72.14 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $264 · 2021: $225 · 2022: $1,100 · 2023: $27.59 · 2024: $551 · 2025: $72.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $525 · Food and Beverage: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $525.00 |
| Food and Beverage | $126.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,100.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $549.67 | 2020-2024 | Imfinzi |
| Genzyme Corporation | $200.00 | 2020 | |
| Covis Pharma Gmbh | $200.00 | 2021 | |
| Pfizer INC. | $53.50 | 2025 | |
| Siemens Medical Solutions USA, INC. | $27.59 | 2023 | Truebeam |
| Genentech USA, INC. | $26.35 | 2024 | Polivy, Lunsumio, Columvi |
| Sumitomo Pharma America, INC. | $18.64 | 2025 | Orgovyx |
| Seagen INC. | $15.15 | 2020 | |
| Acrotech Biopharma INC. | $13.93 | 2021 | |
| Celgene Corporation | $12.48 | 2020 | |
| Merck Sharp & Dohme LLC | $11.78 | 2020 | |
| Epizyme, INC. | $11.50 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Kuzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.